Cysteinyl leukotrienes in eosinophil biology: Functional roles and therapeutic perspectives in eosinophilic disorders

Frontiers in Medicine

Volumn 4, Issue JUL, 2017, Pages

  Thompson Souza, Glaucia A ^a   Gropillo, Isabella ^a   Neves, Josiane S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cysleukotrienes; Cytokine; Eosinophils; Granules; Leukotrienes

Indexed keywords

EID: 85044817876     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2017.00106     Document Type: Review

References (64)

1. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol Res (2014) 6:288-95. doi:10.4168/aair.2014.6.4.288
2. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med (2007) 357:1841-54. doi:10.1056/NEJMra071371
3. Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. Prostaglandins Leukot Essent Fatty Acids (2003) 69:99-109. doi:10.1016/S0952-3278(03)00070-X
4. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev (2007) 27:469-527. doi:10.1002/med.20071
5. Bozza PT, Bakker-Abreu I, Navarro-Xavier RA, Bandeira-Melo C. Lipid body function in eicosanoid synthesis: an update. Prostaglandins Leukot Essent Fatty Acids (2011) 85:205-13. doi:10.1016/j.plefa.2011.04.020
6. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature (1999) 399:789-93. doi:10.1038/21658
7. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem (2000) 275:30531-6. doi:10.1074/jbc.M003490200
8. Panettieri RA, Tan EM, Ciocca V, Luttmann MA, Leonard TB, Hay DW. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol (1998) 19:453-61. doi:10.1165/ajrcmb.19.3.2999
9. Mellor EA, Austen KF, Boyce JA. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med (2002) 195:583-92. doi:10.1084/jem.20020044
10. Ravasi S, Capra V, Mezzetti M, Nicosia S, Rovati GE. A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma. Mol Pharmacol (2000) 57:1182-9
11. Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol (2009) 124:417-21. doi:10.1016/j.jaci.2009.04.020
12. Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol (2009) 124:406-14; quiz 415-6. doi:10.1016/j.jaci.2009.05.046
13. Gauvreau GM, Parameswaran KN, Watson RM, O'Byrne PM. Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med (2001) 164:1495-500. doi:10.1164/ajrccm.164.8.2102033
14. Baptista-dos-Reis R, Muniz VS, Neves JS. Multifaceted roles of cysteinyl leukotrienes in eliciting eosinophil granule protein secretion. Biomed Res Int (2015) 2015:848762. doi:10.1155/2015/848762
15. Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun (2005) 337:281-8. doi:10.1016/j.bbrc.2005.09.052
16. Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W, Jiang Y, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med (2009) 206:2543-55. doi:10.1084/jem.20091240
17. Foster HR, Fuerst E, Lee TH, Cousins DJ, Woszczek G. Characterisation of P2Y(12) receptor responsiveness to cysteinyl leukotrienes. PLoS One (2013) 8:e58305. doi:10.1371/journal.pone.0058305
18. Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem (2013) 288:10967-72. doi:10.1074/jbc.C113.453704
19. Capra V, Ravasi S, Accomazzo MR, Citro S, Grimoldi M, Abbracchio MP, et al. CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation. J Cell Sci (2005) 118:5625-36. doi:10.1242/jcs.02668
20. Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood (2007) 110:3263-70. doi:10.1182/blood-2007-07-100453
21. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J (2006) 25:4615-27. doi:10.1038/sj.emboj.7601341
22. Maekawa A, Balestrieri B, Austen KF, Kanaoka Y. GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci U S A (2009) 106:11685-90. doi:10.1073/pnas.0905364106
23. Travers J, Rothenberg ME. Eosinophils in mucosal immune responses. Mucosal Immunol (2015) 8:464-75. doi:10.1038/mi.2015.2
24. Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids (2003) 69:135-43. doi:10.1016/S0952-3278(03)00074-7
25. Jacob F, Perez Novo C, Bachert C, Van Crombruggen K. Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal (2013) 9:285-306. doi:10.1007/s11302-013-9357-4
26. Neves JS, Radke AL, Weller PF. Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. J Allergy Clin Immunol (2010) 125:477-82. doi:10.1016/j.jaci.2009.11.029
27. Steinke JW, Negri J, Payne SC, Borish L. Biological effects of leukotriene E4 on eosinophils. Prostaglandins Leukot Essent Fatty Acids (2014) 91:105-10. doi:10.1016/j.plefa.2014.02.006
28. Muniz VS, Weller PF, Neves JS. Eosinophil crystalloid granules: structure, function, and beyond. J Leukoc Biol (2012) 92:281-8. doi:10.1189/jlb.0212067
29. Melo RC, Weller PF. Unraveling the complexity of lipid body organelles in human eosinophils. J Leukoc Biol (2014) 96:703-12. doi:10.1189/jlb.3RU0214-110R
30. Spencer LA, Szela CT, Perez SA, Kirchhoffer CL, Neves JS, Radke AL, et al. Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol (2009) 85:117-23. doi:10.1189/jlb.0108058
31. Spencer LA, Melo RC, Perez SA, Bafford SP, Dvorak AM, Weller PF. Cytokine receptor-mediated trafficking of preformed IL-4 in eosinophils identifies an innate immune mechanism of cytokine secretion. Proc Natl Acad Sci U S A (2006) 103:3333-8. doi:10.1073/pnas.0508946103
32. Melo RC, Spencer LA, Dvorak AM, Weller PF. Mechanisms of eosinophil secretion: large vesiculotubular carriers mediate transport and release of granule-derived cytokines and other proteins. J Leukoc Biol (2008) 83:229-36. doi:10.1189/jlb.0707503
33. Melo RC, Spencer LA, Perez SA, Ghiran I, Dvorak AM, Weller PF. Human eosinophils secrete preformed, granule-stored interleukin-4 through distinct vesicular compartments. Traffic (2005) 6:1047-57. doi:10.1111/j.1600-0854.2005.00344.x
34. Melo RC, Spencer LA, Perez SA, Neves JS, Bafford SP, Morgan ES, et al. Vesicle-mediated secretion of human eosinophil granule-derived major basic protein. Lab Invest (2009) 89:769-81. doi:10.1038/labinvest.2009.40
35. Moqbel R, Coughlin JJ. Differential secretion of cytokines. Sci STKE (2006) 2006:e26. doi:10.1126/stke.3382006pe26
36. Melo RC, Weller PF. Piecemeal degranulation in human eosinophils: a distinct secretion mechanism underlying inflammatory responses. Histol Histopathol (2010) 25:1341-54. doi:10.14670/HH-25.1341
37. Erjefalt JS, Greiff L, Andersson M, Adelroth E, Jeffery PK, Persson CG. Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease. Thorax (2001) 56:341-4. doi:10.1136/thorax.56.5.341
38. Spada CS, Nieves AL, Krauss AH, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol (1994) 55:183-91
39. Fregonese L, Silvestri M, Sabatini F, Rossi GA. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy (2002) 32:745-50. doi:10.1046/j.1365-2222.2002.01384.x
40. Saito K, Nagata M, Kikuchi I, Sakamoto Y. Leukotriene D4 and eosinophil transendothelial migration, superoxide generation, and degranulation via beta2 integrin. Ann Allergy Asthma Immunol (2004) 93:594-600. doi:10.1016/S1081-1206(10)61269-0
41. Chan CC, McKee K, Tagari P, Chee P, Ford-Hutchinson A. Eosinophil-eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD4-receptor antagonist. Eur J Pharmacol (1990) 191:273-80. doi:10.1016/0014-2999(90)94159-U
42. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet (1993) 341:989-90. doi:10.1016/0140-6736(93)91073-U
43. Peters-Golden M. Expanding roles for leukotrienes in airway inflammation. Curr Allergy Asthma Rep (2008) 8:367-73. doi:10.1007/s11882-008-0057-z
44. Scott JP, Peters-Golden M. Antileukotriene agents for the treatment of lung disease. Am J Respir Crit Care Med (2013) 188:538-44. doi:10.1164/rccm.201301-0023PP
45. Wang HB, Akuthota P, Kanaoka Y, Weller PF. Airway eosinophil migration into lymph nodes in mice depends on leukotriene C4. Allergy (2016) 72:927-36
46. Bandeira-Melo C, Hall JC, Penrose JF, Weller PF. Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils. J Allergy Clin Immunol (2002) 109:975-9. doi:10.1067/mai.2002.124269
47. Saito H, Morikawa H, Howie K, Crawford L, Baatjes AJ, Denburg E, et al. Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis. Immunology (2004) 113:246-52. doi:10.1111/j.1365-2567.2004.01944.x
48. Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med (2000) 161:1881-6. doi:10.1164/ajrccm.161.6.9907054
49. Becler K, Hakansson L, Rak S. Treatment of asthmatic patients with a cysteinyl leukotriene receptor-1 antagonist montelukast (Singulair), decreases the eosinophil survival-enhancing activity produced by peripheral blood mononuclear leukocytes in vitro. Allergy (2002) 57:1021-8. doi:10.1034/j.1398-9995.2002.23620.x
50. Murray J, Ward C, O'Flaherty JT, Dransfield I, Haslett C, Chilvers ER, et al. Role of leukotrienes in the regulation of human granulocyte behaviour: dissociation between agonist-induced activation and retardation of apoptosis. Br J Pharmacol (2003) 139:388-98. doi:10.1038/sj.bjp.0705265
51. Bandeira-Melo C, Woods LJ, Phoofolo M, Weller PF. Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med (2002) 196:841-50. doi:10.1084/jem.20020516
52. Tedla N, Bandeira-Melo C, Tassinari P, Sloane DE, Samplaski M, Cosman D, et al. Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Sci U S A (2003) 100:1174-9. doi:10.1073/pnas.0337567100
53. Neves JS, Perez SA, Spencer LA, Melo RC, Reynolds L, Ghiran I, et al. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Natl Acad Sci U S A (2008) 105:18478-83. doi:10.1073/pnas.0804547105
54. Jiang Y, Kanaoka Y, Feng C, Nocka K, Rao S, Boyce JA. Cutting edge: interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. J Immunol (2006) 177:2755-9. doi:10.4049/jimmunol.177.5.2755
55. Gonzalez-Cobos JC, Zhang X, Zhang W, Ruhle B, Motiani RK, Schindl R, et al. Store-independent Orai1/3 channels activated by intracrine leukotriene C4: role in neointimal hyperplasia. Circ Res (2013) 112:1013-25. doi:10.1161/CIRCRESAHA.111.300220
56. Neves JS, Weller PF. Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology. Curr Opin Immunol (2009) 21:694-9. doi:10.1016/j.coi.2009.07.011
57. Neves JS, Perez SA, Spencer LA, Melo RC, Weller PF. Subcellular fractionation of human eosinophils: isolation of functional specific granules on isoosmotic density gradients. J Immunol Methods (2009) 344:64-72. doi:10.1016/j.jim.2009.03.006
58. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J (1999) 14:12-8. doi:10.1034/j.1399-3003.1999.14a04.x
59. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy (2001) 56(Suppl 66):7-11. doi:10.1034/j.1398-9995.56.s66.2.x
60. Calhoun WJ. Summary of clinical trials with zafirlukast. Am J Respir Crit Care Med (1998) 157:S238-45. doi:10.1164/ajrccm.157.6.mar6
61. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6-to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA (1998) 279:1181-6. doi:10.1001/jama.279.15.1181
62. Kubavat AH, Khippal N, Tak S, Rijhwani P, Bhargava S, Patel T, et al. A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma. Am J Ther (2013) 20:154-62. doi:10.1097/MJT.0b013e318254259b
63. Sekioka T, Kadode M, Fujii M, Kawabata K, Abe T, Horiba M, et al. Expression of CysLT2 receptors in asthma lung, and their possible role in bronchoconstriction. Allergol Int (2015) 64:351-8. doi:10.1016/j.alit.2015.04.008
64. Gauvreau GM, Boulet LP, FitzGerald JM, Cockcroft DW, Davis BE, Leigh R, et al. CysLT1/2 antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma. Allergy (2016) 71:1721-7. doi:10.1111/all.12987